360 related articles for article (PubMed ID: 37479610)
21. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
[TBL] [Abstract][Full Text] [Related]
22. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
[TBL] [Abstract][Full Text] [Related]
23. Mortality risk after COVID-19 vaccination: A self-controlled case series study.
Xu S; Sy LS; Hong V; Farrington P; Glenn SC; Ryan DS; Shirley AM; Lewin BJ; Tseng HF; Vazquez-Benitez G; Glanz JM; Fireman B; McClure DL; Hurley LP; Yu O; Wernecke M; Smith N; Weintraub ES; Qian L
Vaccine; 2024 Mar; 42(7):1731-1737. PubMed ID: 38388239
[TBL] [Abstract][Full Text] [Related]
24. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.
Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731
[TBL] [Abstract][Full Text] [Related]
25. Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination.
Formeister EJ; Wu MJ; Chari DA; Meek R; Rauch SD; Remenschneider AK; Quesnel AM; de Venecia R; Lee DJ; Chien W; Stewart CM; Galaiya D; Kozin ED; Sun DQ
JAMA Otolaryngol Head Neck Surg; 2022 Apr; 148(4):307-315. PubMed ID: 35201274
[TBL] [Abstract][Full Text] [Related]
26. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
Hause AM; Baggs J; Marquez P; Myers TR; Gee J; Su JR; Zhang B; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1755-1760. PubMed ID: 34968370
[TBL] [Abstract][Full Text] [Related]
27. Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France.
Botton J; Jabagi MJ; Bertrand M; Baricault B; Drouin J; Le Vu S; Weill A; Farrington P; Zureik M; Dray-Spira R
Ann Intern Med; 2022 Sep; 175(9):1250-1257. PubMed ID: 35994748
[TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
30. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
[TBL] [Abstract][Full Text] [Related]
31. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
[TBL] [Abstract][Full Text] [Related]
32. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
Maruyama A; Sawa T; Teramukai S; Katoh N
J Infect Chemother; 2022 Jul; 28(7):934-942. PubMed ID: 35361536
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study.
Andersson NW; Thiesson EM; Baum U; Pihlström N; Starrfelt J; Faksová K; Poukka E; Meijerink H; Ljung R; Hviid A
BMJ; 2023 Jul; 382():e075286. PubMed ID: 37491022
[TBL] [Abstract][Full Text] [Related]
34. Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES
JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
36. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
[TBL] [Abstract][Full Text] [Related]
37. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
38. Safety surveillance of varicella vaccine using tree-temporal scan analysis.
Liu CH; Huang WT; Chie WC; Arnold Chan K
Vaccine; 2021 Oct; 39(43):6378-6384. PubMed ID: 34561139
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
Shoaibi A; Lloyd PC; Wong HL; Clarke TC; Chillarige Y; Do R; Hu M; Jiao Y; Kwist A; Lindaas A; Matuska K; McEvoy R; Ondari M; Parulekar S; Shi X; Wang J; Lu Y; Obidi J; Zhou CK; Kelman JA; Forshee RA; Anderson SA
Vaccine; 2023 Jul; 41(32):4666-4678. PubMed ID: 37344261
[TBL] [Abstract][Full Text] [Related]
40. Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study.
Wright BJ; Tideman S; Diaz GA; French T; Parsons GT; Robicsek A
Lancet Respir Med; 2022 Jun; 10(6):557-565. PubMed ID: 35227415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
